Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank75
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P75
Within normal range
vs 2Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202532.59%
202497.34%
202314.97%
2022-12.57%
20210.00%